Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: A systematic review

Reproductive Biology and Endocrinology

Volumn 9, Issue , 2011, Pages

  Jacobs, Marni ^a   Nassar, Natasha ^a   Roberts, Christine L ^a,b   Hadfield, Ruth ^a   Morris, Jonathan M ^a,b   Ashton, Anthony W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; BIOLOGICAL MARKER; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC ACTIVITY; BLOOD SAMPLING; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL HYPERTENSION; OUTCOME ASSESSMENT; PLASMA; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; REVIEW; SERUM; SMALL FOR DATE INFANT; STILLBIRTH; SYSTEMATIC REVIEW; ADULT; BLOOD; FEMALE; PREGNANCY OUTCOME; RISK FACTOR;

ADULT; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 79958070460     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-9-77     Document Type: Review

References (33)

1. Arroyo JA, Winn VD. Vasculogenesis and angiogenesis in the IUGR placenta. Semin Perinatol 2008, 32(3):172-177. 10.1053/j.semperi.2008.02.006, 18482617.
2. Mayhew TM, Charnock-Jones DS, Kaufmann P. Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta 2004, 25(2-3):127-139. 10.1016/j.placenta.2003.10.010, 14972445.
3. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46(5):1077-1085. 10.1161/01.HYP.0000187899.34379.b0, 16230516.
4. Grill S, Rusterholz C, Zanetti-Dallenbach R, Tercanli S, Holzgreve W, Hahn S, Lapaire O. Potential markers of preeclampsia--a review. Reprod Biol Endocrinol 2009, 7:70. 10.1186/1477-7827-7-70, 2717076, 19602262.
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350(7):672-683. 10.1056/NEJMoa031884, 14764923.
6. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658. 151901, 12618519.
7. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008, 87(8):837-842. 10.1080/00016340802253759, 18607829.
8. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 2009, 4(2):e4453. 10.1371/journal.pone.0004453, 2675175, 19412349.
9. Nevo O, Many A, Xu J, Kingdom J, Piccoli E, Zamudio S, Post M, Bocking A, Todros T, Caniggia I. Placental expression of soluble fms-like tyrosine kinase 1 is increased in singletons and twin pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2008, 93(1):285-292.
10. Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006, 195(6):1668-1673. 10.1016/j.ajog.2006.03.065, 16643817.
11. Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006, 108(2):338-344. 10.1097/01.AOG.0000216014.72503.09, 16880304.
12. Tikkanen M, Stenman UH, Nuutila M, Paavonen J, Hiilesmaa V, Ylikorkala O. Failure of second-trimester measurement of soluble endoglin and other angiogenic factors to predict placental abruption. Prenat Diagn 2007, 27(12):1143-1146. 10.1002/pd.1869, 17960788.
13. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med 2007, 28(2):227-244. 10.1016/j.mam.2007.04.002, 17532461.
14. Kaaja R. Predictors and risk factors of pre-eclampsia. Minerva Ginecol 2008, 60(5):421-429.
15. Higgens JPT, Green S, . eds Cochrane handbook for systematic reviews of interventions. 2008, West Sussex, England: John Wiley & Sons Ltd, eds.
16. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008, 199(3):266. e261-266.
17. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005, 17(1):3-18. 10.1080/14767050400028816, 15804781.
18. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008, 21(5):279-287. 10.1080/14767050802034545, 2846114, 18446652.
19. Eskild A, Jeansson S, Jenum PA, Staff AC, Thadhani R, Karumanchi A, Vatten LJ. Levels of angiogenic factors in pregnancy and post-partum bleeding. Acta Obstet Gynecol Scand 2008, 87(10):1081-1083. 10.1080/00016340802415622, 18792843.
20. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142. 10.1161/HYPERTENSIONAHA.107.087700, 17515455.
21. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007, 109(6):1316-1324. 10.1097/01.AOG.0000265804.09161.0d, 17540803.
22. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775. 10.1210/jc.2003-031244, 14764795.
23. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007, 196(3):239. e231-236.
24. Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006, 91(1):180-184. 10.1210/jc.2005-1076, 16263826.
25. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, Giclas PC, Salmon JE, Holers VM. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010, 117(4):456-462. 10.1111/j.1471-0528.2009.02473.x, 20074261.
26. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010, 122(5):478-487. 10.1161/CIRCULATIONAHA.109.895458, 20644016.
27. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn 2010, 30(3):191-197.
28. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF, Ness RB. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005, 193(1):185-191. 10.1016/j.ajog.2004.11.038, 16021077.
29. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004, 191(4):1240-1246. 10.1016/j.ajog.2004.03.004, 15507947.
30. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008, 21(1):9-23. 10.1080/14767050701830480, 2587364, 18175241.
31. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010, 376(9741):631-644. 10.1016/S0140-6736(10)60279-6, 20598363.
32. Bishop JC, Dunstan FD, Nix BJ, Reynolds TM, Swift A. All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median. Am J Hum Genet 1993, 52(2):425-430. 1682205, 7679245.
33. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002, 22(9):778-782. 10.1002/pd.407, 12224070.